Biogen halts development of Gosuranemab, therapy for rare brain disease
The therapy, Gosuranemab, failed to hit statistical significance in its main goal and did not demonstrate effectiveness on key secondary goals when tested in patients with progressive supranuclear palsy.
New Delhi: Biogen Inc said on Friday it would discontinue the development of its experimental therapy for a rare brain disease after it failed a mid-stage trial.
Read Also: Biogen builds case for its Alzheimers drug aducanumab, skeptics say more data needed
The therapy, Gosuranemab, failed to hit statistical significance in its main goal and did not demonstrate effectiveness on key secondary goals when tested in patients with progressive supranuclear palsy.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd